☰

Chengzhi Zhou, Ph.D. - Publications

Affiliations: 
2007 University of Illinois at Chicago, Chicago, IL, United States 
Area:
Electronics and Electrical Engineering
Tree Info Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Lin G, Wang Z, Chu Q, Hu Y, Huang D, Wang J, Yang F, Zhong W, Zhou C, Zhu B, Ai X, Cao B, Cao Y, Chen M, Chen X, et al. Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic Cancer. PMID 38219795 DOI: 10.1111/1759-7714.15209  0.319
2023 Wang P, Cao L, Tian P, Ren S, Miao L, Zhou C, Fan Y, Li Y, Lv D, Zhao X, Yang M, Zhu C, Yu B, Xu J, Song Y, et al. A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. Cancer Communications (London, England). PMID 37322852 DOI: 10.1002/cac2.12456  0.309
2023 Liu SY, Chen Q, Zhou C, Zhang H, Li W, Chen J, Hu J, Wu L, Chen Q, Dai Q, Shan JZ, Xu F, Liu SM, Wu YL. Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004). Cancer Immunology, Immunotherapy : Cii. PMID 36871274 DOI: 10.1007/s00262-023-03412-8  0.304
2022 Lin X, Deng H, Li S, Xie X, Chen C, Cai L, Yang Y, Qiu G, Xie Z, Qin Y, Liu M, Zhou C. Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study. Journal of Cancer Research and Clinical Oncology. PMID 35146575 DOI: 10.1007/s00432-021-03903-0  0.313
2020 Xie XH, Wang F, Lin XQ, Qin YY, Xie ZH, Zhang JX, Ouyang M, Zhou CZ. Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment. Cancer Management and Research. 12: 12709-12714. PMID 33328765 DOI: 10.2147/CMAR.S278068  0.309
2017 Qin YY, Zhou CZ, Zhu Z, Guan WJ, Lin XQ, Liu CL, Zhou YM, Wu H, Gu YY, Zhang DH, Ou-Yang M, Zhong NS, Li SY. Case report: dermatomyositis associated with lung cancer with heterogeneous morphology. Journal of Thoracic Disease. 9: E1110-E1117. PMID 29312776 DOI: 10.21037/jtd.2017.11.107  0.303
Show low-probability matches.